Exelixis, Inc. (EXEL) stock
Close on Nov 12, 2026Market cap $17.04BP/E 20.9Yield –
Exelixis, Inc. grew revenue 9.1% to $2.50B over the twelve months to Oct 2, 2026. Operating income rose 25.4% to $1.00B, moving the operating margin from 35.0% to 40.2%. Free cash flow was $1.16B, up 48.9% from a year earlier. At the latest close the market valued the company at $17.04B, 20.9 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Oct 2, 2026
Valuation
- Market cap
- $17.04B
- P/E ratio
- 20.9
- Price to sales
- 6.83
- Price to book
- 9.29
- Dividend yield
- –
- Free cash flow yield
- 6.81%
Fundamentals
- Revenue
- $2.50B
- Net income
- $885.14M
- EPS, diluted
- $3.34
- Free cash flow
- $1.16B
- Book value per share
- $7.17
- Diluted shares
- 256M
Trading
- Next earnings
- Jan 11, 2027 (estimated, during market hours)
- Previous close
- $70.70
- Open
- $70.70
- Day's range
- $69.67 – $70.94
- Volume
- 1,631,824
- Average volume (20 days)
- 2,887,170
- Index membership
- S&P MidCap 400, Russell 1000, Russell 3000
- Beta (5 years)
- 0.72
- 52-week range
- $39.71 – $73.69
- RSI (14 days)
- 62.1
- Volatility (1 year)
- 34.0%
- Relative volume
- 0.66×
- WACC
- 8.5%
On 2 of our idea lists: Quality compounders, Buyback cannibals
Index membership is inferred from the holdings of funds that track each index (IJH, SPMD, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | EXEL | S&P 500 | Difference | EXEL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +16.8% | -2.7% | +19.4 pts | ||
| 3 months | +38.6% | -1.7% | +40.4 pts | ||
| Year to date | +59.3% | +11.9% | +47.4 pts | ||
| 1 year | +60.2% | +12.0% | +48.2 pts | ||
| 3 years | +232.6% | +78.2% | +154.4 pts | +49.3% | +21.2% |
| 5 years | +285.9% | +73.2% | +212.6 pts | +31.0% | +11.6% |
| 10 years | +325.9% | +309.6% | +16.2 pts | +15.6% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Exelixis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Exelixis
Biological Products, (No Diagnostic Substances)
Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes targeted medicines for various forms of cancer. Its commercial portfolio features cabozantinib formulations, primarily marketed as CABOMETYX tablets and COMETRIQ capsules, alongside cobimetinib (COTELLIC) and esaxerenone (MINNEBRO). The company focuses on developing small molecules and biotherapeutics, such as antibody-drug conjugates, to treat indications including advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors. Its offerings serve physicians, healthcare providers, and cancer patients, while its clinical pipeline features investigational candidates like zanzalintinib across multiple oncology settings.
Company profile, executives and historyExelixis stock: common questions
What is Exelixis's stock price?
EXEL closed at $69.84 on Nov 12, 2026, down 1.22% on the day. Over the past 52 weeks it traded between $39.71 and $73.69.
What is Exelixis's market cap?
Exelixis was worth $17.04B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is EXEL's P/E ratio?
EXEL trades at 20.9 times earnings, based on diluted earnings per share of $3.34 over the twelve months to Oct 2, 2026.
How much revenue does Exelixis make?
Exelixis reported revenue of $2.50B for the twelve months to Oct 2, 2026, up 9.1% from a year earlier.
Does Exelixis pay a dividend?
No. Exelixis has not paid a cash dividend over the last twelve months.
When does Exelixis report earnings next?
Exelixis is expected to report Q4 FY2026 results on Jan 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has EXEL stock performed over the past year?
Including dividends, EXEL returned +60.2% over the past year, against +12.0% for the S&P 500.
How many EXEL shares are sold short?
26M shares were sold short at the latest FINRA report, 11.53% of the float, or 11.7 days of average trading volume.
Who are Exelixis's competitors?
Companies most similar to Exelixis by business, industry and size include MRNA, NBIX, BNTX, HALO, BCRX.
See a number that looks wrong?